Results 131 to 140 of about 1,506,940 (201)

Evaluation of Anti-Inflammatory Activity of the New Cardiotonic Steroid γ-Benzylidene Digoxin 8 (BD-8) in Mice. [PDF]

Cells
Ferreira DA, Medeiros ABA, Soares MM, Lima ÉA, Oliveira GCSL, Leite MBDS, Machado MV, Villar JAFP, Barbosa LA, Scavone C, Moura MT, Rodrigues-Mascarenhas S.   +11 more
europepmc   +1 more source

Individual and Combined Cardioprotective Effects of 1,25(OH)₂D₃ and Dimethyl Fumarate in an Isoproterenol-Induced Myocardial Injury Model. [PDF]

J Biochem Mol Toxicol
Karpuzoğlu FH, Kilinç S, Sözmen İ, Bingül İ, Aydin AF, Bayram A, Önder S, Akçe E, Doğru-Abbasoğlu S, Uysal M.   +9 more
europepmc   +1 more source

Cardiovascular Protection with Sulfasalazine During Doxorubicin Challenge: Evidence from Oxidative and Histologic Endpoints. [PDF]

Biomolecules
Ozhan O, Kaya E, Tasolar MH, Balkar ME, Yildiz A, Dogru F, Ulutas Z, Kucukakcali Z, Parlakpinar H.   +8 more
europepmc   +1 more source

Development of CPA-Catalyzed β-Selective Reductive Amination of Cardenolides for the Synthesis and Biological Evaluation of Hydrolytically Stable Analogs. [PDF]

Chemistry
Perry N, Eid S, Schmitt-Ulms G, Nagorny P.   +3 more
europepmc   +1 more source

Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia. [PDF]

J Vet Med Sci
Hirao D, Morita S, Hasegewa H, Yoshimura A, Kawaguchi T, Yamada S, Oomori T, Suzuki K, Fukushima R.   +8 more
europepmc   +1 more source

Levosimendan in Cardiac Arrest (LeiCA): Protocol for a Randomized, Double-Blind, Phase II Clinical Trial. [PDF]

Acta Anaesthesiol Scand
Rysz S, Flam B, Hedberg M, Galmén K, Mårtensson J, Djärv T, Jonsson Fagerlund M.   +6 more
europepmc   +1 more source

Mechanistic Insights into the Antihypertensive and Cardioprotective Actions of Corosolic Acid: A Narrative Review. [PDF]

Molecules
Chen F, Tew WY, Ong MT, Yam MF.
europepmc   +1 more source

Procedural Characteristics and Safety of Slender Percutaneous Coronary Intervention: Slender Is Better. [PDF]

Catheter Cardiovasc Interv
Yoshimachi F, Yamaji K, Kohsaka S, Kawamura Y, Kasai S, Fujii T, Nagamatsu H, Amano K, Karasawa Y, Yamada S, Nakagawa Y, Ikari Y.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The therapeutic potential of novel cardiotonic agents

Expert Opinion on Investigational Drugs, 2003
During the course of treatment of heart failure patients, cardiotonic agents are inevitable for improvement of myocardial dysfunction. Clinically available agents, such as beta-adrenoceptor agonists and selective phosphodiesterase 3 inhibitors, act mainly via cyclic AMP/protein kinase A-mediated facilitation of Ca(2+) mobilisation (upstream mechanism).
exaly   +3 more sources